Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model (Q38346533)

From Wikidata

Jump to navigation Jump to search

scientific article published on September 2003

Language	Label	Description	Also known as
English	Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model	scientific article published on September 2003

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

0 references

1 reference

based on heuristic

inferred from title

breast neoplasm

1 reference

based on heuristic

inferred from title

author name string

Dawn N Waterhouse

1

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Karen A Gelmon

2

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Dana Masin

3

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Marcel B Bally

4

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

publication date

1 September 2003

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Journal of Experimental Therapeutics & Oncology

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

261-271

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Prognostic value of the quantitative measurement of the oncoprotein p185(Her-2/neu) in a group of patients with breast cancer and positive node involvement

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01099.X

21 January 2018

Prognostic value of c-erbB2 expression in breast cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01099.X

21 January 2018

Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01099.X

21 January 2018

Sp1 binding plays a critical role in Erb-B2- and v-ras-mediated downregulation of alpha2-integrin expression in human mammary epithelial cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01099.X

21 January 2018

HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01099.X

21 January 2018

ErbB2 pathways in heart and neural diseases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01099.X

21 January 2018

Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01099.X

21 January 2018

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01099.X

21 January 2018

Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01099.X

21 January 2018

Inhibition of erbB-2-positive breast cancer cell growth by erbB-2 antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01099.X

21 January 2018

Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01099.X

21 January 2018

HER2/neu antisense targeting of human breast carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01099.X

21 January 2018

Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01099.X

21 January 2018

Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01099.X

21 January 2018

Molecular mechanisms of action of antisense drugs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01099.X

21 January 2018

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01099.X

21 January 2018

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01099.X

21 January 2018

Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01099.X

21 January 2018

Identifiers

10.1111/J.1533-869X.2003.01099.X

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38346533&oldid=1755382878"